Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT

Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT

Background: Neuroprotective drugs are needed to slow or prevent neurodegeneration and disability accrual in secondary progressive multiple sclerosis. Amiloride, fluoxetine and riluzole are repurposed drugs with potential neuroprotective effects. Objectives: To assess whether or not amiloride, fluoxe...

Full description

Bibliographic Details
Main Authors: Floriana De Angelis, Peter Connick, Richard A Parker, Domenico Plantone, Anisha Doshi, Nevin John, Jonathan Stutters, David MacManus, Ferran Prados, Ian Marshall, Bhavana Solanky, Rebecca S Samson, Frederik Barkhof, Sebastien Ourselin, Marie Braisher, Moira Ross, Gina Cranswick, Sue H Pavitt, Sharmilee Gnanapavan, Gavin Giovannoni, Claudia AM Gandini Wheeler-Kingshott, Clive Hawkins, Basil Sharrack, Roger Bastow, Christopher J Weir, Nigel Stallard, Siddharthan Chandran, Jeremy Chataway
Format: Article
Language:English
Published: NIHR Journals Library 2020-05-01
Series:Efficacy and Mechanism Evaluation
Subjects:
research design
drug repositioning
amiloride
fluoxetine
riluzole
neuroprotection
multiple sclerosis
multiple sclerosis chronic progressive
atrophy
neurodegenerative diseases
magnetic resonance imaging
Online Access:https://doi.org/10.3310/eme07030

Internet

https://doi.org/10.3310/eme07030

Similar Items